Last reviewed · How we verify
A Double-Blind Randomized Phase 2.5 Trial of ONY-P1 Vaccine Versus Placebo in Men With D0 Prostate Cancer Following Limited Androgen Ablation
RATIONALE: Vaccines made from tumor cells may help the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase II trial is studying vaccine therapy to see how well it works compared with a placebo in treating patients with stage D0 prostate cancer.
Details
| Lead sponsor | Kael-GemVax Co., Ltd. |
|---|---|
| Phase | Phase 2 |
| Status | UNKNOWN |
| Enrolment | 54 |
| Start date | 2007-03 |
Conditions
- Prostate Cancer
Interventions
- BCG vaccine
- prostate cancer vaccine ONY-P1
- placebo
Primary outcomes
- Time to PSA progression
Countries
United States